Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of VentriGel in Post-MI Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02305602
Recruitment Status : Completed
First Posted : December 2, 2014
Last Update Posted : October 25, 2019
Information provided by (Responsible Party):
Ventrix, Inc.

Brief Summary:
This Phase I, open label, study will investigate the effects of VentriGel injection in patients who have experienced a first, large ST elevation myocardial infarction (STEMI) treated by PCI within the past 3 years and have evidence of left ventricular remodeling.

Condition or disease Intervention/treatment Phase
Myocardial Infarction Heart Failure Left Ventricular Remodeling Biological: VentriGel Phase 1

Detailed Description:
Evaluate the safety and feasibility of VentriGel delivered trans-endocardially to subjects with left ventricular ejection fraction (LVEF) 25 to 45% secondary to MI. Secondary endpoints will look at efficacy variables of ESV, EDV, EF, scar mass.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction
Actual Study Start Date : September 2015
Actual Primary Completion Date : September 5, 2018
Actual Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: Post Myocardial Infarction
VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
Biological: VentriGel
VentriGel will be injected via MyoStar catheter after NOGA mapping

Primary Outcome Measures :
  1. Incidence of serious adverse events that occur within 6 months of injection [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject is 30-75 years of age
  2. The subject must be able to provide informed consent
  3. At least 60 days and no more than 3 years will have passed since the first ST elevation myocardial infarction (Index STEMI) at time of VentriGel administration
  4. The Index STEMI must meet the following criteria:

    1. First time diagnosis of STEMI AND;
    2. Meet the STEMI criteria of the American College of Cardiology (ACC)/American Heart Association (AHA) (e.g. ST elevation in at least 2 contiguous leads >0.2 mV in V1, V2 or V3 and/or >0.1mV in at least two other leads), or new left bundle branch block (LBBB)
  5. Evidence of left ventricular remodeling secondary to the myocardial infarction using 2-D echocardiography or cMR;

    1. the LVEF must be ≥ 25% and ≤ 45% AND;
    2. The left ventricular wall thickness is ≥ 8 mm in target area.
  6. Successful percutaneous coronary intervention (PCI) restoring TIMI II of higher flow to infarcted area
  7. Negative pregnancy test [serum human chorionic gonadotropin (βhCG)] in women of childbearing potential within 24 hours prior to dosing) or if less than 2 years postmenopausal agree to use of adequate contraception during the study.
  8. Must be ambulatory, willing and able to comply with protocol, including follow-up visits
  9. Subject must be receiving best medical treatment for their post-MI clinical presentation according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
  10. For those subjects indicated for heart failure medical therapy, subjects must be on stable therapy including beta-blockers and angiotensin converting enzyme inhibitors, if tolerated, for at least 45 days prior to therapy delivery

Exclusion Criteria:

  1. Contraindications to cardiac MR
  2. NYHA Functional Classification 4 heart failure within the prior 6 months.
  3. Significant coronary artery stenosis that may require percutaneous or surgical revascularization within six months of enrollment, as determined by the principal investigator
  4. Left ventricular thrombus, left ventricular aneurysm, subjects with post-infarction pericarditis, or subjects with wall motion abnormalities outside the region of the infarct related artery
  5. Frequent, recurrent, sustained (>30 seconds) ventricular tachycardia in 30 days prior to VentriGel administration
  6. ECG or 24 hour Holter Monitor with any of the following findings:

    • Bifascicular block (left bundle branch block or right bundle branch block plus left hemi-block)
    • Higher grade AV block (i.e. 3rd degree)
    • Ventricular tachycardia (>= 5 seconds of VT OR any symptomatic VT)
  7. Atrial fibrillation with heart rate greater than 110 bpm.
  8. Severe valvular disease (e.g. aortic stenosis of moderate or worse severity, valvular insufficiency requiring surgical repair) or history of heart valve replacement.
  9. Known allergy to porcine proteins or prior implantation of a porcine derived medical product including cardiac valves or other ECM products.
  10. Etiology of heart failure due to any cause (e.g. hypertrophic cardiomyopathies, restrictive cardiomyopathies, constrictive pericardial disease, amyloidosis, active myocarditis) other than the index MI.
  11. Severe peripheral vascular disease that impairs femoral arterial access.
  12. Less than 3 years, cancer free, since end of treatment for cancer (with exception of basal cell carcinoma)
  13. Alcohol or drug dependency within six months prior to enrollment
  14. Cerebrovascular event within the 90 days prior or major surgical procedure or major trauma within the 14 days prior to enrollment
  15. Participation, defined as receiving test article, in an experimental clinical study within 30 days prior to administration of VentriGel (i.e. screen failure from other study does not exclude subject)
  16. Uncontrolled hypertension defined as systolic blood pressure (SBP) > 180 mmHg and/or or diastolic blood pressure (DBP) >110 mmHg
  17. Abnormal laboratory values as defined below performed at screening:

    • Aspartate aminotransferase [AST]/ alanine aminotransferase [ALT] ≥ 3 times upper limit of normal (ULN)
    • Serum creatinine ≥ 2.0 mg/dL
    • Platelet count < 50,000/mm3
    • Hemoglobin < 9.0 g/dL
    • HbA1c > 9.0%
    • PT or aPTT with clinically significant elevations relative to local laboratory norms
  18. Any other cardiac or non-cardiac conditions or illness which, in the opinion of the principal investigator, may place subjects at undue risk or compromise the objectives of the study.
  19. Institutional interpretation of cMR EF data outside the ≥ 25% and ≤ 45% limits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02305602

Layout table for location information
United States, Arizona
Mercy Gilbert Medical Center
Gilbert, Arizona, United States, 85297
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Florida
University of Florida
Gainesville, Florida, United States, 32606
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Minnesota
Minneapolis Heart Institute
Minneapolis, Minnesota, United States, 55407
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Ventrix, Inc.
Layout table for additonal information
Responsible Party: Ventrix, Inc. Identifier: NCT02305602    
Other Study ID Numbers: CV-201
First Posted: December 2, 2014    Key Record Dates
Last Update Posted: October 25, 2019
Last Verified: October 2019
Keywords provided by Ventrix, Inc.:
extracellular matrix
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Ventricular Remodeling
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Pathological Conditions, Anatomical